Although SGLT2 inhibitors have demonstrated a reduction in heart failure outcomes [3–6], even in non-diabetic patients [22] mechanisms to explain the cardiovascular benefits of these drugs are not clearly understood. Here, SLC5A2 is linked to heart failure.